Lebon, C.; Neubauer, H.; Berdugo, M.; Delaunay, K.; Markert, E.; Becker, K.; Baum-Kroker, K.S.; Prestle, J.; Fuchs, H.; Bakker, R.A.;
et al. Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic Retinopathy. Pharmaceutics 2021, 13, 1105.
https://doi.org/10.3390/pharmaceutics13081105
AMA Style
Lebon C, Neubauer H, Berdugo M, Delaunay K, Markert E, Becker K, Baum-Kroker KS, Prestle J, Fuchs H, Bakker RA,
et al. Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic Retinopathy. Pharmaceutics. 2021; 13(8):1105.
https://doi.org/10.3390/pharmaceutics13081105
Chicago/Turabian Style
Lebon, Cecile, Heike Neubauer, Marianne Berdugo, Kimberley Delaunay, Elke Markert, Kolja Becker, Katja S. Baum-Kroker, Jürgen Prestle, Holger Fuchs, Remko A. Bakker,
and et al. 2021. "Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic Retinopathy" Pharmaceutics 13, no. 8: 1105.
https://doi.org/10.3390/pharmaceutics13081105
APA Style
Lebon, C., Neubauer, H., Berdugo, M., Delaunay, K., Markert, E., Becker, K., Baum-Kroker, K. S., Prestle, J., Fuchs, H., Bakker, R. A., & Behar-Cohen, F.
(2021). Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic Retinopathy. Pharmaceutics, 13(8), 1105.
https://doi.org/10.3390/pharmaceutics13081105
